The Board is comprised of experienced and successful pharmaceutical and biotechnology executives and investors.

Donald Parfet, MBA
Chairman of the Board
Mr. Parfet chairs the Board. He is also the Managing Director of the Apjohn Group and General Partner of Apjohn Ventures Fund. Prior to founding the Apjohn Group, Don was a Senior Vice President at Pharmacia. At Pharmacia, Don's responsibilities included all of the associated businesses including Animal Health, Diagnostics, Pharmaceutical Commercial Services and Plasma Products. Additionally, Don oversaw the company's investments in Amersham Pharmacia Biotech and Biacore International AB.Don serves on the boards of directors of Kelly Services, Inc. and MPI Research, Inc. Don received his BA degree in economics from the University of Arizona in 1975 and his M.B.A. degree in finance from the University of Michigan in 1977.

Robert Forgey, MBA
Chief Operating Officer
Mr. Forgey graduated Beta Gamma Sigma from Olin School of Business, Washington University in 2001. He holds both a Bachelor's and a Master's degree in Biology from the University of North Dakota. He has 15 years pharmaceutical industry experience in research and development with G.D. Searle, Pharmacia and Pfizer development. His responsibilities have been in molecular biology methods development, project support, business management and financial control of discovery research organizations. Mr. Forgey most recently served as Manager, Discovery Financial Business Administration/Senior Financial Analyst with Pfizer-Pharmacia. Prior to this he served as Leader, Oncology Operations in Pharmacia Discovery.

Michael E. Pape, PhD
Dr. Pape serves on the Board of Directors of the Michigan Biosciences Industry Association (MichBio), and serves as a scientific advisor to the Apjohn Group. He has been in the pharmaceutical industry since 1989, and has published numerous articles on various aspects of atherosclerosis, diabetes and gene regulation. Most recently, Dr. Pape served as Vice President, Cellular and Molecular Biology at Esperion, a biopharmaceutical company that was acquired by Pfizer in 2003. Prior to co-founding Esperion, Dr. Pape was a research associate in the department of molecular biology at Parke-Davis. There he played an integral role in several small molecule drug discovery and research projects, which focused on gene regulation in lipoprotein metabolism and atherosclerotic disease. Dr. Pape started his career at Pharmacia-Upjohn, and received his B.S. degree in Microbiology from the University of Michigan, and his Ph.D. in Biochemistry from Purdue University.

Mina Sooch, MBA
Ms. Sooch is a general partner at Apjohn Ventures and brings with her over a decade of pharmaceutical, healthcare, and chemical experience as an entrepreneur, strategy and finance advisor, and chemical engineer. She has led the investments in Asterand (Detroit), Nephros (Ann Arbor) and Afmedica (Kalamazoo). Ms. Sooch spent 8 years at Monitor Group, a top tier global strategy consulting firm serving Fortune 500, private, and public clients. Ms. Sooch received a MBA from Harvard Business School in 1993. She graduated summa cum laude with highest distinction from Wayne State University in 1989 with a B.S. in Chemical Engineering.